Skip to Main Content

The Departments of Anesthesiology and Neurology Host: “Perivascular Spaces in the Brain & Contributions to Pathology of Cerebral Small Vessel Disease” on March 24

February 05, 2020

The Departments of Anesthesiology and Neurology host: Perivascular Spaces in the Brain & Contributions to Pathology of Cerebral Small Vessel Disease

Perivascular space and cerebral small vessel disease mini-symposium March 24 in the Brady Memorial Auditorium 1:30-4:30pm

Sponsored by the Leducq Foundation

The panel will feature the following speakers:

  • Keynote Speaker: Joanna M. Wardlaw (Professor of Applied Neuroimaging and Director of Edinburgh Imaging, University of Edinburgh) “Perivascular Spaces in the Brain: Anatomy, Physiology, and Contributions to Pathology of Small Vessel Disease”
  • Jaime Grutzendler, MD (Professor of Neurology and Neuroscience): “Optical Interrogation of Neurovascular and Myelin Pathophysiology in the Live Mammalian Brain”   
  • Miriam Treggiari, MD PhD (Professor of Anesthesiology): “Delayed cerebral ischemia in SAH - mechanisms and opportunities for intervention”
  • Keynote Speaker Philip Bath (Professor of Stroke Medicine, University of Nottingham): “Pharmacological treatment and prevention of cerebral small vessel disease: a review of potential interventions”
  • Moderator: Helene Benveniste, MD, PhD (Professor of Anesthesiology)

Contact: Jennifer Vissagio Jennifer.vissagio@yale.edu  203 785 3358

Host Organizations: Anesthesiology and Neurology

Precis: Cerebral small vessel disease (cSVD) are a group of disorders that result from pathological alteration of the small blood vessels in the brain and rank as the most common pathology in vascular dementia. Of the nearly 35-36 million people that are estimated to suffer from dementia worldwide, up to 65% have an cSVD component. Unfortunately, the prevalence of SVD is increasing and effective disease-modifying interventions are yet to be found. In recent years, there has been tremendous growth in new diagnostic information, a greater understanding of cSVD risk factors as well as instigation of new large clinical trials of repurposed drugs in cSVD to prevent dementia and stroke.

Submitted by Robert Forman on February 05, 2020